We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology of Invasive Candidiasis in Patients with Hematologic Malignancy on Antifungal Prophylaxis

  • Review
  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

The landscape of invasive Candida infections in patients with hematologic malignancy has evolved due to the adoption of anti-fungal prophylaxis, advances in oncological therapies, and developments in antifungal therapies and diagnostics. Despite these scientific gains, the morbidity and mortality caused by these infections remain unchanged, highlighting the importance of an updated understanding of its epidemiology. Non-albicans Candida species are now the predominant cause of invasive candidiasis in patients with hematological malignancy. This epidemiological shift from Candida albicans to non-albicans Candida species is partially a consequence of selective pressure from extensive azole use. Further analysis of this trend suggests other contributing factors including immunocompromise caused by the underlying hematologic malignancy and the intensity of its associated treatments, oncological practices, and regional or institution specific variables. This review characterizes the changing distribution of Candida species in patients with hematologic malignancy, describes the causes driving this change, and discusses clinical considerations to optimize management in this high-risk patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Centers for Disease Control and Prevention. Hematologic Cancer Incidence, Survival, and Prevalence. USCS Data Brief, no. 30. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022.

  2. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with haematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52. https://doi.org/10.1002/cncr.24507.

    Article  CAS  PubMed  Google Scholar 

  3. Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective cohort multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7. https://doi.org/10.1111/1469-0691.12312.

    Article  CAS  PubMed  Google Scholar 

  4. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R, et al. Increase in C krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;326:1274–7. https://doi.org/10.1111/1469-0691.12312.

    Article  Google Scholar 

  5. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidemia and cancer: patients are not all the same. BMC Infect Dis. 2006;6:1–7. https://doi.org/10.1186/1471-2334-6-50.

    Article  Google Scholar 

  6. Solberg CO, Meuwissen HJ, Needham RN, Good RA, Matsen JM. Infectious complications in bone marrow transplant patients. Br Med J. 1971;1(5739):18–23. https://doi.org/10.1136/bmj.1.5739.18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bays DJ, Thompson GR. Fungal infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin N Am. 2019;33:545–66. https://doi.org/10.1016/j.idc.2019.02.006.

    Article  Google Scholar 

  8. Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: a narrative review. Eur J Int Med. 2016;34:21–8. https://doi.org/10.1016/j.ejim.2016.06.029.

    Article  Google Scholar 

  9. Jaimu AT, Albertyn J, Sebolai OM, Pohl CH. Update on Candida krusei, a potential multidrug-resistant pathogen. Med Mycol. 2021;59:14–30. https://doi.org/10.1093/mmy/myaa031.

    Article  CAS  Google Scholar 

  10. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2496 patients: data from the prospective antifungal therapy (PATH) registry 2004–2008. PLoS ONE. 2014;9(7):e101510. https://doi.org/10.1371/journal.pone.0101510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703. https://doi.org/10.1086/599039.

    Article  CAS  PubMed  Google Scholar 

  12. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1-50. https://doi.org/10.1093/cid/civ933.

    Article  PubMed  Google Scholar 

  13. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373:1445–56. https://doi.org/10.1056/NEJMra1315399.

    Article  CAS  PubMed  Google Scholar 

  14. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The Changing epidemiology of invasive Candidiasis. Cancer. 2008;112(11):2493–9. https://doi.org/10.1002/cncr.23466.

    Article  PubMed  Google Scholar 

  15. Van Burik JH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against IFIs during neutropenia in patients undergoing hematologic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16. https://doi.org/10.1086/422312.

    Article  PubMed  Google Scholar 

  16. Chen X-C, Xu J, Wu D-P. Clinical characteristics and outcomes of breakthrough candidemia in 71 hematological malignancy and/or allogeneic hematopoietic stem cell transplant recipients: a single center retrospective study from China, 2011–2018. Clin Infect Dis. 2020;71(suppl 4):S394–9. https://doi.org/10.1093/cid/ciaa1523.

    Article  CAS  PubMed  Google Scholar 

  17. Criscuolo M, Marchesi F, Candoin A, Cattaneo C, Nosari A, Veggia B, et al. Fungaemia in haematological malignancies: SEIFEM-2015 survey. Eur J Clin Invest. 2019;49(5):e13083. https://doi.org/10.1111/eci.13083.

    Article  PubMed  Google Scholar 

  18. El Baradei A. A decade after the emergence of Candida auris: what do we know? Eur J Clin Microbiol Infect Dis. 2020;39(9):1617–27. https://doi.org/10.1007/s10096-020-03886-9.

    Article  Google Scholar 

  19. Bergamasco MD, Pereira CA, Arrais-Rodrigues C, Ferreira DB, Baiocchi O, Kerbauy F, et al. Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach. J Fungi (Basel). 2021;7:588. https://doi.org/10.3390/jof7080588.

    Article  CAS  PubMed  Google Scholar 

  20. Kontoyiannis DP, Marr KA, Park BJ, Alexander BJ, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–100. https://doi.org/10.1086/651263.

    Article  PubMed  Google Scholar 

  21. Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia. 2009;168:299–311. https://doi.org/10.1007/s11046-009-9188-6.

    Article  PubMed  Google Scholar 

  22. Colombo AL, Agnelli C, Kontoyiannis DP. Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients. J Antimicrob Chemother. 2021;76:543–6. https://doi.org/10.1093/jac/dkaa446.

    Article  CAS  PubMed  Google Scholar 

  23. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006;162:1–15. https://doi.org/10.1007/s11046-006-0025-x.

    Article  PubMed  Google Scholar 

  24. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–55. https://doi.org/10.1056/NEJM199203263261301.

    Article  CAS  PubMed  Google Scholar 

  25. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospection, randomized, double-blind study. J Infect Dis. 1995;171:1545–52. https://doi.org/10.1093/infdis/171.6.1545.

    Article  CAS  PubMed  Google Scholar 

  26. Marr K, Seidel K, Slavin M, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055–61.

    Article  CAS  PubMed  Google Scholar 

  27. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59. https://doi.org/10.1056/NEJMoa061094.

    Article  CAS  PubMed  Google Scholar 

  28. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230. doi: https://doi.org/10.1093/jac/dky286.

  29. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(7):882–913. https://doi.org/10.6004/jnccn.2016.0093.

    Article  CAS  PubMed  Google Scholar 

  30. Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–97. https://doi.org/10.1111/imj.12595.

    Article  CAS  PubMed  Google Scholar 

  31. Little JS, Aleissa MM, Beluch K, Gonzalez-Bocco IH, Marty FM, Manne-Goehler J, et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv. 2022;6(16):4821–30. https://doi.org/10.1182/bloodadvances.2022007474.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32(6):538–45. https://doi.org/10.1097/QCO.0000000000000611.

    Article  CAS  PubMed  Google Scholar 

  33. Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, et al. EORTC infectious diseases group. Epidemiology and outcome of fungemia in a cancer cohort of the infectious diseases group (IDG) of the European organization for research and treatment of cancer (EORTC 65031). Clin Infect Dis. 2015;61(3):324–31. https://doi.org/10.1093/cid/civ293.

    Article  PubMed  Google Scholar 

  34. Nucci M, Silveira MI, Spector N, Silveira F, Velasco E, Martins CA, et al. Fungemia in cancer patients in Brazil: predominance of non-albicans species. Mycopathologia. 1998;141(2):65–8. https://doi.org/10.1023/a:1006951619245.

    Article  CAS  PubMed  Google Scholar 

  35. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997;10:444–65. https://doi.org/10.1128/CMR.10.3.444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Marinach-Patrice C, Fekkar A, Atanasova R, Gomes J, Djamdjian L, Brossas JY, et al. Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS ONE. 2010;5(1):e8862. https://doi.org/10.1371/journal.pone.0008862.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Seftel MD, Ho M, Pruthi D, Orbanski S, Rubinger M, Schacter B, et al. High rate of discordance between clinical and autopsy diagnoses in blood and marrow transplantation. Bone Marrow Transpl. 2007;40(11):1049–53. https://doi.org/10.1038/sj.bmt.1705855.

    Article  CAS  Google Scholar 

  38. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91:986–9.

    PubMed  Google Scholar 

  39. Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal susceptibility testing: current approaches. Clin Microbiol Rev. 2020;33(3):e00069-e119. https://doi.org/10.1128/CMR.00069-19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from, et al. to 2011. J Clin Microbiol. 2008;2012(50):3435–42. https://doi.org/10.1128/JCM.01283-12.

    Article  CAS  Google Scholar 

  41. Kontoyiannis DP (2009) Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the infectious diseases society of America. Clin Infect Dis. 49(4):638–9; author reply 639–40. doi: https://doi.org/10.1086/603585

  42. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–82. https://doi.org/10.1056/NEJMoa066906.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA

    Margaret E. McCort & Helen Tsai

Authors
  1. Margaret E. McCort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret E. McCort.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Handling Editor: Ferry Hagen

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCort, M.E., Tsai, H. Epidemiology of Invasive Candidiasis in Patients with Hematologic Malignancy on Antifungal Prophylaxis. Mycopathologia 188, 885–892 (2023). https://doi.org/10.1007/s11046-023-00754-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-023-00754-w

Keywords

Search

Navigation